Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Michael Desborough

BMedSci(Hons), MB ChB, FRCP, FRCPath, DPhil


Consultant Haematologist & Honorary Senior Lecturer

The main focus of my research is assessing whether desmopressin could be used for treatment of thrombocytopenia or platelet dysfunction.  

Platelets are a key part of clot formation. Patients with too few platelets, or platelets which are dysfunctional, are vulnerable to bleeding. One way to treat these patients is by transfusing platelets from a blood donor but this approach is often not effective. I am aiming to determine if desmopressin (a drug which increases platelet adhesion by stimulating release of Von Willebrand Factor) could be an effective adjuvant, or alternative treatment.  

I am using a combination of methods to assess the value of desmopressin in this setting including meta-analysis of randomised controlled trials; laboratory assessment of thrombus formation under flow; and observational trials. I am leading two randomised placebo-controlled feasibility trials: desmopressin for prevention of bleeding in thrombocytopenia (DRIVE) and desmopressin for treatment of stroke due to haemorrhage (DASH).

Key publications

Recent publications

More publications

ORCID

0000-0002-1951-5616